Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 13, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,075,000 ordinary shares of 25 pence each.
- Purchase Price: 1,367.89 pence per share.
- Treasury Holdings Post-Transaction: 219,589,678 shares.
- Shares in Issue (excluding Treasury): 5,769,593,165 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. Following the transaction on November 13, 2006, the company increased its treasury stock holdings to approximately 219.6 million shares. The filing does not provide comparative data against prior periods for this specific metric.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying the 1,075,000 shares by the 1,367.89 pence price.
- Confirm the updated total share capital structure (5,769,593,165 shares in issue plus 219,589,678 treasury shares).
- Review the May 17, 2006 Annual General Meeting minutes to confirm the scope of the share buyback authority utilized.
- Note that this filing does not contain quarterly or annual financial performance data.